Influenza

Dr. Greenberg urges the ACIP to update their vaccine guidelines for patients 65 years and older to recommend high-dose flu vaccines.

The application for NVX-CoV2373 is supported by promising data from 2 multinational trials conducted prior to the spread of the Omicron variant.

New data show "nocebo responses" are frequent in COVID-19 vaccine studies—which may drive recipients' expectation of side effects.

More than 70% of parents of children with asthma said they in favor of the influenza vaccine during the COVID-19 pandemic.

Dr. Talbot speaks to the variety of different strains of influenza, and how research into different flu vaccines could be informed by advancements made in the management of shingles and COVID-19.

Deaths attributed to pneumonia, influenza, and COVID-19 were above the epidemic threshold, per the latest CDC report.

An expert explains how flu monitoring, sequencing, and preventive strategies may be improved due to the pandemic.

Despite heightened public worry over "florona" cases, a meta analysis from China suggests co-infection of the respiratory viruses is not associated with more severe outcomes.

A public health expert discusses how the future of COVID-19 may be managed similarly to flu—and why vaccination efforts are similarly burdened.

A pair of experts discussed the importance of differentiating early signs of either disease on a recent podcast.

The expert explains what recent vaccine innovations may come to influenza products.

Amid rising cases of both respiratory viruses, here is a guide for symptoms, complications, disease onset and illness duration.

CDC data suggest children and young adults are increasingly affected, with the circulating subtype being one associated with a high risk of burden.

Cross-sectional data from the last decade of flu seasons show pregnant women are infrequently vaccinated and at greater risk of severe disease.

Dr. Al Rizzo highlights the best insights and opinions from featured guests this last year.

Influenza A has been the dominant strain during the current influenza season.

The relative risk reduction was 94% in patients 65 years of age or older in clinical trials.